Last updated: May 31, 2026
ecutive summary
No complete, accurate supplier map can be produced from the information provided. A defensible list of specific suppliers for “dextroamp saccharate,” “dextroamp sulfate,” “amphetamine aspartate,” and “amphetamine sulfate” requires shipment, registration, and/or verified sourcing evidence tied to named manufacturers (API and finished-dose), with jurisdictional linkage to FDA registrations and (for generics/brand) Orange Book and DMF records. Without those primary identifiers, any supplier list would be incomplete or incorrect.
What supplies DEXTROAMP saccharate, AMP aspartate, DEXTROAMP sulfate and AMP sulfate APIs in the US market?
Featured snippet answer: A complete supplier list requires verified API manufacturer identities tied to FDA DMF/registration records and finished-dose sourcing. The inputs given do not include the required identifiers.
Which supplier categories exist for amphetamine salts?
- API manufacturers (chemical synthesis of the salt form)
- Finished-dose manufacturers that buy API and formulate (tablets, capsules, oral solutions)
- Intermediate/salt-form suppliers (salt conversion from base amphetamine streams)
What evidence is typically used to identify “suppliers” in due diligence?
- FDA Active Pharmaceutical Ingredient (Drug Master File) listings tied to specific salt forms
- FDA Establishment Registration and Product Listing for the final drug label
- Orange Book “Applicant/Manufacturer” identity for the specific NDA ANDA(s)
- Contract manufacturing disclosures in labeling or case filings
Which companies are API suppliers for DEXTROAMP sulfate and AMP sulfate?
Featured snippet answer: Supplier identification is established via FDA-linked DMF and registration records; it cannot be derived reliably from the salt names alone.
What makes sulfate vs aspartate vs saccharate sourcing different?
- Salt formation changes purification specs, polymorph/solid-state profile, and hygroscopicity control
- Finished-dose performance (bioavailability and tablet/capsule behavior) can drive which vendors are qualified
How do salt forms affect qualification and supply continuity?
- Different suppliers may have different control strategies for crystal form and water content
- Vendor qualification commonly relies on CoA history, stability data, and process consistency
What companies supply DEXTROAMP saccharate and AMP aspartate?
Featured snippet answer: Supplier identification requires salt-form-specific evidence from DMFs and/or FDA product registrations.
What role do salt-form conversion and solid-state controls play?
- Salt-form crystallization and conversion steps require validated process windows
- Solid-state testing can disqualify otherwise compatible supply sources
What due-diligence artifacts are used in procurement?
- DMF cross-reference reports for the exact salt form
- Audit reports and supplier quality agreements (template-level review is insufficient)
How do FDA Orange Book listings identify manufacturers and supply chain entities for these amphetamine salts?
Featured snippet answer: Orange Book lists NDA/ANDA applicants and patent-listed manufacturers for the specific drug product, not raw-material suppliers. Mapping “suppliers” requires linking those product manufacturers to API sourcing evidence.
What to look for on Orange Book for each amphetamine salt drug product
- NDA/ANDA holder (applicant)
- Dosage form and strength
- Patent holder and “listed” patents (where present)
- Manufacturer identity as reflected in submission metadata
What generic entry risks exist if you rely on a single API supplier for amphetamine salts?
Featured snippet answer: Single-supplier reliance increases operational and regulatory risk; generic entry risk is driven by patent status and regulatory/CMC comparability, which cannot be assessed from salt names alone.
Where supply risk shows up operationally
- Batch lead times during API crystallization and drying
- Tight schedules for salt-formulary adjustments if polymorph shifts occur
Where supply risk shows up legally/regulatorily
- CMC comparability challenges when changing API manufacturing site or solid-state profile
- Potential adverse events if dissolution profile shifts affect exposure
What manufacturing/IP barriers affect switching suppliers for DEXTROAMP/AMP salt APIs?
Featured snippet answer: Barriers are governed by DMF ownership/access, qualification history, and process validation; they cannot be mapped without named filings and controlled references.
Common switching constraints
- Locked DMF references with limited letters of access
- Proprietary crystallization conditions and in-process controls
- Required stability program continuity across supply changes
Key Takeaways
- The salt names alone are insufficient to produce a complete, accurate supplier list for DEXTROAMP saccharate, AMP aspartate, DEXTROAMP sulfate, and AMP sulfate.
- A defensible supplier map requires FDA-linked evidence (DMFs, registrations, Orange Book mapping to product manufacturers) tied to the exact drug products and salt forms.
FAQs
-
How do I identify the API manufacturers for DEXTROAMP sulfate from public records?
Use FDA DMF identifiers and cross-referenced submissions for the exact salt form, then validate with product-level manufacturer data.
-
Does Orange Book list raw-material API suppliers for amphetamine salts?
Orange Book lists NDA/ANDA applicants and listed patent information for drug products; API suppliers require additional FDA DMF/registration linkage.
-
What evidence is strongest for qualifying a second-source API for AMP aspartate?
DMF letters of access, CoA traceability for the exact salt form, and demonstrated bioequivalence-relevant solid-state control.
-
What risks increase when changing suppliers between sulfate and aspartate salts?
Solid-state differences and dissolution performance variability drive CMC risk and can require bridging/validation.
-
Can procurement due diligence rely only on vendor capability statements for amphetamine APIs?
Capability statements are not sufficient; qualification depends on regulatory-file linkage and validated process/solid-state consistency.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Master Files (DMF) and Active Pharmaceutical Ingredient (API) records. U.S. Food and Drug Administration.
